Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
April 24, 2024 10:00 ET
|
Autolus Therapeutics plc
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL at ASCO
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
April 23, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
April 22, 2024 16:30 ET
|
Cellectis Inc.
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs at ASGCT 2024
CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors
April 15, 2024 16:05 ET
|
Cargo Therapeutics, Inc.
SAN MATEO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell...
Global and China Passenger Car T-Box Industry Research 2024 Featuring 8 International Suppliers and 31 Chinese Suppliers
April 09, 2024 07:18 ET
|
Research and Markets
Dublin, April 09, 2024 (GLOBE NEWSWIRE) -- The "Global and China Passenger Car T-Box Market Report, 2024" report has been added to ResearchAndMarkets.com's offering.Global and China Passenger Car...
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
April 08, 2024 16:30 ET
|
Cellectis Inc.
Cellectis announces that preliminary data exploring novel TALEN® editing process in HSPCs will be presented at ASGCT 2024
Monthly information on share capital and company voting rights
April 04, 2024 16:30 ET
|
Cellectis Inc.
PARIS, April 04, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
April 02, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics announces acceptance of MAA by the EMA for obe-cel for patients with B-ALL
Autolus Therapeutics Announces Changes to its Board of Directors
April 01, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Announces Changes to its Board of Directors
Global CAR-T Cell Therapy Market Expected to Surge to USD 34.04 Billion by 2034 with a CAGR of 23.33%
March 27, 2024 08:50 ET
|
Research and Markets
Dublin, March 27, 2024 (GLOBE NEWSWIRE) -- The "Global CAR-T Cell Therapy Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. The global...